FCX CLASS ACTION: BFA Law Alerts Freeport-McMoRan Inc. Investors of the Pending Securities Fraud Class Action and Upcoming January 12 DeadlineNovember 18, 2025 3:33 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 18, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company's senior executives for securities fraud after significant ...

Core Viewpoint - Rosen Law Firm is reminding KBR, Inc. investors of the November 18, 2025 deadline to join a securities class action lawsuit related to misleading statements made by the company during the Class Period from May 6, 2025, to June 19, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased KBR securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit alleges that KBR made materially false and misleading statements regarding its partnership with HomeSafe and the ability to fulfill the Global Household Goods Contract, which led to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4].

New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your Stride, Inc. (NYSE: LRN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/stride-inc-lawsuit-submission-form-3?prid=177999&wire=5&utm_campaign=30or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.THE LAWSUIT: A cl ...

Core Insights - Bicycle Therapeutics plc is under investigation for possible violations of federal securities laws, as announced by Levi & Korsinsky [1] - RBC Capital Markets downgraded Bicycle Therapeutics from Outperform to Sector Perform due to delays in the development of its drug, zelenectide pevedotin, which is intended for metastatic urothelial cancer [2] - Following the downgrade, Bicycle's American Depositary Receipt (ADR) price dropped over 7% on the same day [3] Company Developments - The delay in the drug's development is attributed to the decision to push dose selection to the first quarter of 2026, which raises concerns about increased competition in the urothelial cancer treatment market [2] - The competitive landscape is highlighted by the potential impact of a competing product from Pfizer, which may benefit from any further delays in Bicycle's drug development [2] Legal Context - Levi & Korsinsky LLP has a strong reputation in securities litigation, having secured significant settlements for shareholders and being recognized as one of the top firms in the United States for securities class actions [4]

Core Insights - Lexin Solutions has launched its MiLi solution on SAP Store, integrating with SAP S/4HANA via SAP Business Technology Platform Integration Suite to enhance indirect materials management [2][11] - The MiLi platform provides real-time supply chain intelligence, inventory optimization, and improved data integrity for organizations in asset-intensive sectors [1][4] Company Overview - Lexin Solutions, founded in 2022 and headquartered in Brisbane, aims to eliminate operational inefficiencies in heavy industries through its MiLi platform, which offers end-to-end visibility and control over indirect materials [13] - The company is a partner in the SAP PartnerEdge program, which supports partners in developing innovative applications [12] Product Features - MiLi features a modular architecture, allowing businesses to scale at their own pace and select functionalities relevant to their operations [6] - The platform standardizes material master data, optimizes inventory, and enables quick searches for parts, vendors, or work orders [7] - Role-based workflows and real-time dashboards enhance user experience and decision-making capabilities [8] Implementation and ROI - A baseline connection to SAP S/4HANA can be established within 2-4 hours, with customers typically breaking even within six months post-implementation [9] - Lexin Solutions offers a MiLi Lite Pilot to simulate live operations, with a guarantee of at least 10x savings on pilot costs or the service is free [10]

Core Insights - DelphX Capital Markets Inc. is advancing its Quantem Crypto Securities (QCS) as a fully-collateralized hedging solution in the digital asset sector [1][4] - The recent decline in Bitcoin prices from above US$115,000 to below US$90,000 highlights the need for institutional-grade hedging tools [2][4] - A U.S. primary dealer is evaluating a potential collaboration to implement QCS within its digital-asset infrastructure, indicating growing interest in the product [3] Company Overview - DelphX focuses on developing and distributing structured products, including fixed-income and cryptocurrency solutions through its special purpose vehicle, Quantem LLC [5] - The company offers proprietary products such as Collateralized Put Options (CPOs) and Collateralized Reference Notes (CRNs) to provide protection against rating downgrades and cryptocurrency losses [7] Market Context - The crypto market is characterized by high risk and significant volatility, necessitating sophisticated risk-management tools like QCS for capital preservation and competitive positioning [4] - Institutional adoption of digital assets is accelerating, creating demand for effective hedging solutions [4]

Core Insights - Robohub and ESG Partners Inc. are participating in the inaugural Canada Climate Week Xchange (CCWX) to explore the application of robotics and AI in climate solutions [1][2] - The event titled "Harnessing Robotics & AI For Climate Solutions" will take place during CCWX from November 24 to November 30, 2025 [2][6] Company Overview - Robohub is a collaborative robotics research facility aimed at advancing cutting-edge robotics research through collective efforts of faculty members and their teams [4] - ESG Partners Inc. focuses on helping mid-market organizations navigate environmental, social, and governance (ESG) practices to enhance operational resilience and stakeholder trust [5] Event Details - The event "Harnessing Robotics & AI For Climate Solutions" is scheduled for November 25, 2025, at 6 PM EST, located at the University of Waterloo [7] - CCWX is a five-year initiative aimed at uniting Canadians to address climate-related challenges through collaboration [6]

Core Insights - FingerMotion, Inc. is focusing on expanding its technology platforms and monetizing its core competencies developed in China for broader regional markets [1][2] - The company aims to build an ecosystem linking telecommunications, data analytics, and service platforms while adapting to local requirements [3][4] Strategic Priorities - Strengthening core operations by improving operational efficiency and technological capabilities in China [8] - Productizing existing intellectual property, analytics models, and platform capabilities for targeted regional markets [8] - Pursuing strategic collaborations and acquisitions to support scale, distribution, and purposeful expansion into new markets [8] Company Vision - FingerMotion envisions rapidly growing its user base through organic means, aiming to serve over 1 billion users in the China market and eventually expand to other regional markets [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a class action lawsuit related to securities purchased between February 5, 2025, and July 23, 2025 [1] Group 1: Class Action Details - Investors who purchased Molina securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3] - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [5] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4] - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its success in securities class action settlements [4] Group 3: Case Specifics - The lawsuit claims that Molina's financial guidance for fiscal year 2025 was likely to be cut due to undisclosed issues related to medical cost trends and service utilization, which ultimately misled investors about the company's prospects [5]

Core Insights - Lifordi Immunotherapeutics has secured a strategic investment from Sanofi Ventures, along with additional funding from existing investors, totaling $112 million to support its clinical development efforts [1][6][7] Group 1: Investment Details - The investment from Sanofi Ventures and existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture will support an ongoing Phase 1 study of LFD-200, an antibody-drug conjugate (ADC) targeting rheumatoid arthritis [1][6] - The funding will also facilitate Chemistry Manufacturing and Controls (CMC) preparations to ensure timely availability of Phase 2 clinical supplies [1][6] Group 2: Clinical Development - The Phase 1 study of LFD-200 is progressing as planned, with initial data from healthy participants expected in the coming months [6][7] - Preclinical studies have shown efficacy in multiple disease models by targeting myeloid and lymphoid cells using a specific cell surface membrane protein [7] Group 3: Company Overview - Lifordi Immunotherapeutics is focused on developing ADCs for autoimmune and inflammatory disorders, leveraging a novel drug delivery platform applicable to various payloads [7] - The company is backed by experienced drug developers in immunology and inflammatory diseases, along with a strong track record in partnerships and funding [7]